Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources.
Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations.
Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages.
Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry.
This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry.
Hashtag: #SIICCapital #MicroPort #SHMAF
The issuer is solely responsible for the content of this announcement.
About MicroPort Scientific Corporation
Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation.
About SIIC Capital
As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Ceconomy enters talks with China's JD.com for potential takeover
German electronics retailer Ceconomy, which operates MediaMarkt and Saturn brands, is engaged in advanced talks with Chinese e-commerce company over a possible voluntary public takeover. is contemplating a cash offer of €4.60 per ordinary share, compliant with the German Securities Acquisition and Takeover Act, according to Ceconomy's statement of 24 July 2025. No binding agreements have yet been reached, and it remains uncertain whether a formal takeover offer will proceed. The Chinese company disclosed its interest in a potential deal towards the end of 2023. Reuters reports that a proposed transaction could value the company at approximately €2.2bn ($2.59bn). Ceconomy's largest shareholder is the Kellerhals family, while the Haniel family owns 17%. Meridian, Beisheim and Freenet hold smaller stakes. 36.3% of Ceconomy's shares are freely traded. MediaMarkt and Saturn manage 1,030 stores across multiple European countries and employ 50,000 staff, as of 30 September 2024. The brands also operate a major online electronics retail platform. In the 2023/24 financial year, Ceconomy recorded total sales of €22.4bn, of which €5.1bn were online. According to Bloomberg, logistics division's delivery network could enhance the operations of Ceconomy's physical retail outlets. In the first quarter of 2025, reported net revenues of $41.5bn and net income attributable to the company's ordinary shareholders of $1.5bn. The Chinese company launched an export-to-domestic sales programme in April, 2025, with plans 'to procure no less than 200bn yuan worth of export-oriented goods for domestic sales'. In August 2024, Walmart sold its stake in to raise $3.74bn, a term sheet seen by Reuters has revealed. The decision was part of the US retailer's strategy to focus on its own operations within China. Walmart sold 144.5 million American depositary shares priced between $24.85 and $25.85. "Ceconomy enters talks with China's for potential takeover" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Cheetah Mobile to Acquire Controlling Stake in UFACTORY to Accelerate Its Robotics Commercialization Strategy
BEIJING, July 28, 2025 /PRNewswire/ -- Cheetah Mobile Inc. (NYSE: CMCM) ("Cheetah Mobile" or the "Company"), a China-based IT company, today announced that one of its majority-owned subsidiaries has signed a definitive agreement to acquire an equity interest of 60.8% in Shenzhen UFACTORY Technology Co., Ltd. ("UFACTORY"), a leading provider of lightweight robotic arms, for a total consideration of approximately RMB99.5 million. Prior to the transaction, another wholly-owned subsidiary of Cheetah Mobile already held 19.2% of UFACTORY's total equity interest. Following the transaction, the two subsidiaries will collectively hold approximately 80.0% of UFACTORY's total equity interest, representing Cheetah Mobile's ultimate beneficial ownership in UFACTORY of approximately 75.8%. The transaction has been approved by the Company's board of directors and audit committee and is expected to close in the third quarter of 2025, subject to customary closing conditions. Mr. Sheng Fu, Cheetah Mobile's Chairman and Chief Executive Officer, commented, "We're excited to deepen our investment in UFACTORY, a fast-growing leader in collaborative robotics. With its robust technology stack and lean go-to-market approach, UFACTORY is an ideal partner to support our next stage of growth in AI and robotics. With this acquisition, we're strengthening our product portfolio to help our service robots operate across more physical environments and tasks. This marks a significant step forward in our mission to deliver smarter, more adaptable robotics solutions to global markets." Mr. Thomas Ren, Cheetah Mobile's Director and Chief Financial Officer, commented: "We will fund the acquisition with our cash reserves. As of March 31, 2025, we held over USD230 million in net cash, giving us ample flexibility to pursue strategic investments that have the potential to deliver sustainable shareholder value." About UFACTORY UFACTORY is a leading provider of lightweight collaborative robotic arms - designed to safely work alongside humans in shared environments. Under the brand "UFACTORY xArm", the company is one of the few robotic arm providers generating net profits and substantial revenue from overseas markets, having achieved sustained growth over the past years. Backed by proprietary full-stack robotics technologies, UFACTORY offers a diverse portfolio of five-, six-, and seven-axis robotic arms and robotic accessories. UFACTORY's developer-friendly design makes its robotic arms and accessories highly adaptable across different use cases, empowering customers with flexibility and ease of deployment. UFACTORY has built a loyal, global customer base with increasing revenues from international markets. About Cheetah Mobile Inc. Cheetah Mobile is a China-based IT company with a commitment to AI innovation. It has attracted hundreds of millions of users through an array of internet products and services on PCs and mobile devices. At the same time, it actively engages in the independent research and development of AI technologies, including LLM technologies. Cheetah Mobile provides advertising services to advertisers worldwide, value-added services including the sale of premium membership to its users, multi-cloud management platform to companies globally, as well as service robots to international clients. Cheetah Mobile is also committed to leveraging its cutting-edge AI technologies, including LLM technologies, to empower its products and make the world smarter. It has been listed on the New York Stock Exchange since May 2014. Safe Harbor Statement This press release contains forward-looking statements. These statements, including management quotes and business outlook, constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in the forward-looking statements, including but are not limited to the following: Cheetah Mobile's growth strategies; Cheetah Mobile's ability to retain and increase its user base and expand its product and service offerings; Cheetah Mobile's ability to monetize its platform; Cheetah Mobile's future business development, financial condition and results of operations; competition with companies in a number of industries including internet companies that provide online marketing services and internet value-added services; expected changes in Cheetah Mobile's revenues and certain cost or expense items; and general economic and business condition globally and in China. Further information regarding these and other risks is included in Cheetah Mobile's filings with the U.S. Securities and Exchange Commission. Cheetah Mobile does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Investor Relations Contact Helen Jing ZhuCheetah Mobile +86 10 6292 7779Email: ir@ View original content: SOURCE Cheetah Mobile Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
28 minutes ago
- Yahoo
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
